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Abstract 
Background: 
Ischaemic Preconditioning (IPC) is a strategy to reduce Ischaemia Reperfusion (IR) injury. Its 
benefit in human liver transplantation is unclear. The aim of this study was to analyse the 
current evidence for donor IPC in liver transplantation. 
Methods: 
Systematic review and meta-analysis of studies involving IPC of liver transplant donors. Ovid 
Medline, Embase and Cochrane CENTRAL were searched up until January 2015.  Data retrieved 
included the primary outcomes of 1 year mortality, incidence of Primary Graft Non-Function 
(PGNF) and re-transplantation. Secondary outcomes included Aspartate Aminotransferase 
(AST) levels on day 3 post-op. Pooled Odds Ratios (OR) were calculated for dichotomous data 
and Mean Weighted Ratios for continuous data. 
Results: 
Ten studies included 593 patients (286 IPC; 307 Control). IPC was associated with a reduction 
in mortality at 1 year (6% vs 11%) although this was not statistically significant  (OR 0.54, 95% 
C.I. 0.28 to 1.04, p=0.06). The IPC group had a significantly lower day 3 AST level (WMD -
66.41iU, p=0.04). 
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Conclusions: 
This meta-analysis demonstrates that IPC reduces liver injury following transplantation and 
produces a large reduction in 1 year mortality which was not statistically significant. 
Confirmation of clinical benefit from IPC requires an adequately powered prospective RCT. 
 
Introduction: 
Liver transplantation is the only effective treatment for both acute and chronic liver failure. 780 
deceased donor liver transplants were performed in the UK in 2014-2015[1]. Due to a recent 
widening of the eligibility criteria, demand for this scarce resource far outstrips supply of 
suitable organs. The use of grafts from extended criteria donors in the UK has expanded to meet 
demand with the use of grafts from donors following cardiac death (DCD) increasing from 6.9% 
in 2005[2] to 19.1% of grafts inserted in 2013[1]. Ischaemia Reperfusion (IR) injury is the 
injury that happens to an organ when its blood supply is interrupted and reconstituted and is a 
major cause of morbidity, mortality and graft loss following liver transplantation - accounting 
for up to 10 per cent of early graft loss from brain dead donors (DBD)[3]. DCD grafts are 
associated with a two fold increase in risk of graft loss and recipient mortality in UK centres[2]. 
A key factor to the reduced outcomes seen with the use of DCD grafts is their susceptibility to IR 
injury and the associated complications. There are no current accepted treatments for IR injury 
and as such the development of strategies to prevent or reduce IR injury is a key research goal. 
Ischaemic preconditioning (IPC) was first described in 1986[4]. This process of inducing short 
periods of non-lethal ischaemia to a target organ has been shown to provide protection to the 
same or other organs during a subsequent sustained ischaemic insult. The reduction of liver 
damage with IPC has been demonstrated in different small animal models of hepatic 
ischaemia[5][6] but its role in clinical transplantation remains to be proven. Several small trials 
have investigated IPC in the donor prior to organ recovery. 
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The aim of this study was to evaluate the current evidence in the medical literature regarding 
the use of IPC in human liver transplantation. 
Methods: 
This systematic review and meta-analysis was performed according to the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) statement[7]. The study protocol 
was registered with the University of York Centre for Reviews and Dissemination international 
prospective register of systematic reviews (2015:CRD42015016055). 
The medical literature was searched for RCT’s examining the effect of IPC in the clinical setting 
of deceased donor liver transplantation. 
All trials including patients undergoing deceased donor liver transplantation were included in 
the study. Patients undergoing living donor liver transplantation were excluded. 
Data was retrieved from the published studies. The primary outcomes chosen for the analysis 
were early graft failure and retransplantation within 3 months and mortality within 1 year. The 
secondary outcomes were episodes of acute rejection, length of time spent in the intensive 
therapy unit (ITU) and in hospital, number of days ventilated, incidence of post-operative 
transient renal support, infective complications and Aspartate transferase (AST) on the 3rd post 
operative day[8]. Papers were included irrespective of language. Both RCTs and matched cohort 
studies were included. Studies based on overlapping cohorts of patients were excluded. 
MEDLINE, Embase and Cochrane Central Register of Controlled Trials (CENTRAL) databases 
were searched up to and including the second week of January 2015 using the following search 
algorithm: ((((hepatic OR liver) adj3 (transplant$ or graft$)).ti,ab.) or (exp Liver 
Transplantation/)) and (((isch?emic adj(preconditioning or pre conditioning or pre-
conditioning)).ti,ab.) or (exp Ischaemic Preconditioning/)). 
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Two authors independently reviewed the titles. Appropriate studies were identified and those 
appropriate following review of abstracts were sourced in full. Two authors independently 
extracted data from the studies selected for full paper review. Disagreements were resolved by 
consensus or where necessary by the senior author. 
 
Statistical analysis: 
Data on the selected primary and secondary outcomes were entered into a meta-analysis. 
Dichotomous outcomes were analysed based on event rates using pooled odds ratio (OR) while 
continuous outcomes were analysed using a weighted means difference (WMD). The analysis 
was performed on Revman 5® software (The Nordic Cochrane Centre, Copenhagen, Denmark) 
using a random effects DerSimonian-Laird model and results were reported with 95% 
confidence intervals. A p value of less than 0.05 or an Odds ration not crossing 1 was considered 
to be significant. Heterogeneity was assessed using τ2, χ2, and Ι2 measures and was deemed 
significant if p<0.10 or Ι2 was greater than 30%. In keeping with Revman’s default setting trials 
with zero events in each arm of a variable were excluded from the analysis of that variable. If a 
variable had zero events in one arm, 0.5 events was added to that arm to allow an odds ratio 
and confidence intervals to be calculated. 
 
Results: 
Following the initial search (Fig 1), 458 studies were identified of which 305 remained 
following removal of duplicates. The 305 titles and abstracts were reviewed and 19 studies 
were selected for full review. Reasons for study exclusion were animal model (125), review, 
editorial or reply (73), irrelevant topic (64), no full text or abstract available (20) and 
duplicated patient data set (4). 
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Of the 19 studies reviewed in detail 9 were excluded – reasons for exclusion were conference 
abstracts (7), duplicated patient dataset (1) and living donor study (1). 
Data from ten studies were further analysed[9] [10] [11] [12] [13] [14] [15] [16] [17] [18] which 
included 593 patients (286 IPC; 307 Control). The characteristics and results of each study are 
included in Tables 1 and 2. Only DBD grafts were included in these studies. No grafts underwent 
normothermic machine perfusion or reperfusion. There was no significant difference in mean 
length of cold ischaemic time between the treatment and control arms of the included studies. 
 
Primary endpoints: 
Seven studies[9] [10] [11] [12] [13] [14] [15] (475 patients: 232 IPC, 243 control) included data 
on 1 year mortality (Fig 2). There was significant variability in the timepoint at which patient 
mortality was calculated from 3 months up to 1 year. There was no significant heterogeneity 
between the studies (I2=0%, p=0.85). IPC was associated with a 45% reduction in post-
operative mortality (6% vs 11%) but this was not statistically significant (OR 0.54, 95% C.I. 0.28 
to 1.04, p=0.06). 
Five studies[9] [10] [11] [12] [15] (322 patients: 152 IPC, 170 control) provided data on the 
incidence of primary graft non-function (PGNF) (Fig 3). There was no significant heterogeneity 
between the studies (I2=0%, p=0.91). The IPC group had a lower incidence of PGNF (0.7% vs 
4%) but this was not statistically significant (OR 0.35, 95% C.I. 0.009 to 1.31, p=0.12). 
Six studies[10] [11] [12] [14] [15] [16] (274 patients: 182 IPC, 192 control) commented on the 
need for retransplantation (Fig 4). There was no significant heterogeneity between the studies 
(I2=0%, p=0.99). IPC was associated with a reduction in the incidence of retransplantation (3% 
vs 4%) but this was not significant (OR 0.83, 95% c.i. 0.28 to 2.41, p=0.73). 
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Secondary endpoints: 
Three studies[11][12][18] (149 patients: 68 IPC, 81 control) included data on day 3 AST levels 
(Fig 5). There was no significant heterogeneity between the studies (I2=0%, p=0.46). AST levels 
on the 3rd post operative day were significantly lower in patients who had been transplanted 
with grafts from IPC treated donors compared to controls (WMD -66.41 (-129.92 to -2.89) iU, 
p=0.04). 
Four studies[9] [10] [13][16] (240 patients: 121 IPC, 119 control) included data on length of ITU 
stay (Fig 6). There was no significant heterogeneity between the studies (I2=0%, p=0.74). IPC 
was associated with an increase in length of ITU stay but this was not statistically significant 
MWD 1.21 (-1.02 to 3.45) days (p=0.29). 
Six studies[9] [10] [11] [12] [13] [16] (362 patients: 174 IPC, 188 control) included data on 
length of hospital stay (Fig 7). There was significant heterogeneity between the studies 
(I2=56%, p=0.06) IPC was associated with an increase in length of total hospital stay but this 
was not statistically significant MWD 0.56 (-4.77 to 5.9) days (p=0.84). 
Seven studies[9] [12] [13] [15] [16] [17] [18] (435 patients; 210 IPC, 225 control) included data 
on number of patients experiencing an episode of acute rejection (Fig 8). There was significant 
heterogeneity between the studies (I2=37%, p=0.14). IPC was associated with a reduction in 
number of patients experiencing an episode of acute rejection (20% vs 25%) but this was not 
statistically significant (OR 0.71 95% c.i. 0.39 to 1.31, p=0.28). 
 
Discussion: 
IPC is an inexpensive intervention that has been shown to ameliorate hepatic IR injury in small 
animal models[19] [20] [21]. Several small human trials have investigated IPC of donor livers 
prior to recovery of organs. The majority of these trials have been pilot feasibility trials and 
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none have been adequately powered to determine a significant benefit in terms of the most 
important clinically relevant outcomes of patient morbidity and mortality following liver 
transplantation. An audit of liver transplant activity in the UK demonstrated that 90 day patient 
and graft survival is 90.8% and 89.3% respectively[22] and as such designing a trial around 
these end-points would be difficult due to the required trial size and associated cost. A meta-
analysis investigating the benefit of this intervention in liver transplantation is therefore of 
importance as a meta-analysis of underpowered trials may reveal significant results. 
A Cochrane review involving a literature search performed in early 2007 included 3 RCTs and 
failed to show any clinical benefit from IPC[23]. Several further RCTs have been performed 
since this time justifying a further review of the literature.  
IPC was associated with 45% reduction in recipient mortality post liver transplantation (6% vs 
11%). This large reduction in mortality from a single intervention did not prove to be 
statistically significant. Similarly IPC was associated with an 82% reduction in the incidence of 
grafts loss secondary to PGNF (0.7% vs 4%) although this again this was not significant 
(p=0.12).  This data demonstrating lower recipient mortality and graft loss post liver transplant 
in patients who had received a graft from donors undergoing IPC was not statistically significant 
but would suggest that a larger prospective randomised trial is required which is powered to 
demonstrate a reduction in these clinically significant end points. A power calculation was 
performed with an alpha error of 0.05 and a beta error of 0.2 for both PGNF and 1 year 
mortality. This calculated that total sample size of 660 patients with 330 in each arm would be 
required to adequately power a trial to demonstrate a significant reduction in PGNF and a 
sample size of 974 with 487 patients in each arm would be necessary to demonstrate a 
significant reduction in 1 year mortality. Such a multi-centre trial would be feasible in the UK. 
Recent work has shown that AST levels on the 3rd day following liver transplant, rather than 
peak transaminase levels, correlate with recipient mortality rate and the incidence of graft loss, 
need for organ support and incidences of post operative complications and infections[8]. Day 3 
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AST was therefore included as a secondary end point for this meta-analysis. Three studies 
measured AST levels on day 3. Patients that received a graft that underwent IPC had 
significantly lower AST levels on the 3rd post operative day.  
A significant reduction in an important surrogate marker for post transplant outcomes would 
again suggest a beneficial effect to donor IPC and would also support the need for a further 
clinical trial. 
Patients who received grafts from donors who underwent IPC spent on average 1 day longer in 
ITU and in 0.6 days longer in hospital. Neither of these were significant but both of these 
variables are associated with adverse outcomes following liver transplant including a greater 
need for organ support or the development of complications post transplantation. A large 
randomised clinical trial is further supported to ensure that donor IPC is not associated with 
any adverse outcomes. 
All of the included trials were small and underpowered to detect a significant reduction in 
important clinical end points which could lead to inconclusive results from this meta-analysis. 
Eight studies were randomised controlled trials with little evidence of bias and a low drop out 
rate post randomisation. 
There was significant variability between trials. There is no consensus regarding the optimal 
preconditioning stimulus in humans. Of the 10 trials included, 9 trials performed a single IPC 
stimulus of 10 minutes whilst only one trial performed a single IPC stimulus of 5 minutes [14]. 
Furthermore there is a lack of validated end-points in clinical trials of liver transplantation and 
as such the end points measured in individual trials varied significantly making comparison of 
the trials difficult. Very few trials reported on the incidence of specific post-operative 
complications including infections. The incidence of these complications reflects underlying 
graft function however we were unable to comment on the effects of IPC on these important 
end-points. 
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Two trials which were included were cohort studies[16][17], comparing a cohort of patients 
undergoing IPC to a historical matched cohort. Although cohort studies provide less robust 
evidence than a randomised clinical trial, neither of these trials were included in the analysis 
involving AST levels which were significantly reduced by IPC. 
Only one trial included marginal grafts in a subgroup analysis[16]. This cohort study 
demonstrated a reduction in IR injury both in normal and marginal grafts following IPC and a 
reduction in incidence of acute rejection in marginal grafts that underwent IPC when compared 
to controls. This study raises the important question of whether IPC is more efficacious in grafts 
subjected to a more significant IR injury. It was the only study to perform a sub group analysis 
of extended criteria grafts. A trial investigating the value of IPC or RIPC specifically with 
extended criteria donors including including DCD donors prior to withdrawal of circulatory and 
ventilator support would be warranted. 
No trial investigated recipient outcome longer than one year post-operatively and as such the 
long term effect of IPC on post transplant outcomes remains unknown. Furthermore data 
regarding recipient quality of life post transplantation was not included. This is an important 
end point in liver transplantation as the aim of transplantation is not only to improve survival 
but also to improve quality of life. 
This analysis has shown that donor IPC prior to graft recovery results in a reduction in acute 
liver injury as indicated by reduced day 3 AST levels and major but not statistically significant 
reduction in one year mortality and incidence of PGNF. An adequately powered multi centred 
RCT is required to confirm the harms of benefits of donor ischaemic preconditioning to 
recipients undergoing liver transplantation. 
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Table 1: Summary of included trials. 
Author (year) Amador et al 
(2005)9 
Cescon et al 
(2006)10 
Cescon et al 
(2009)11 
Franchello et al 
(2009)12 
Azoulay et al 
(2005)13 
Duration of IPC 10 minutes 10 minutes 10 minutes 10 minutes 10 minutes 
Group IPC Ctl IPC Ctl IPC Ctl IPC Ctl IPC Ctl 
No in group 30 30 23 24 19 20 30 45 46 45 
1 year mortality 0 2 0 2 3 2 1 3 2 2 
Incidence of PGNF 0 3 0 1 0 1 0 1 0 0 
Incidence of  
re-transplantation 
- - 2 2 1 1 1 2 0 0 
Day 3 AST levels 
(iU/L) 
644 819 - - - - 270.12 
(193.74) 
281.46 
(292.94) 
- - 
Length of ITU stay 
(days) 
6.8 
(8) 
6.7 
(7) 
- - - - - - 15 
(14) 
12 (6) 
Length of hospital 
stay (days) 
24 
(14) 
24 
(14) 
- - - - 13.4 
(6.6) 
18.12 
(12.92) 
38 
(25) 
31 (12)
Incidence of episodes 
of acute rejection 
4 4 - - - - 9 7 9 12 
 
Table 2: Summary of included trials ctd. 
Author (year) Koneru et al 
(2005)14 
Koneru et al 
(2007)15  
Degli-Eposti et 
al (2011)16  
Jassem et al 
 (2006)17  
Fuggle et al 
(2009)18 
Duration of IPC 5 minutes 10 minutes 10 minutes 10 minutes 10 minutes 
Group IPC Ctl IPC Ctl IPC Ctl IPC Ctl IPC Ctl 
No in group 34 28 50 51 26 24 9 14 19 16 
1 year mortality - - 6 11 0 0 0 0 - - 
Incidence of PGNF 0 0 1 1 - - 0 0 - - 
Incidence of  
re-transplantation 
0 1 1 1 1 1 - - - - 
Day 3 AST levels 
(iU/L) 
183 
(126-
2311) 
183 
(108-
316) 
- - - - - - 120 
(91) 
216 
(137) 
Length of ITU stay 
(days) 
- - - - 12/15 11/12 1 2.8 - - 
Length of hospital 
stay (days) 
- - 10 10 28/52 29/33 - - - - 
Incidence of episodes 
of acute rejection 
- - 6 11 4 11 2 7 7 5 
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Fig 1: PRISMA flow chart.  
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Fig 2: Forest plot comparing mortality between the groups. 
 
 
 
Fig 3: Forest plot comparing incidence of PGNF between the groups. 
 
 
 
Fig 4: Forest plot comparing incidence of re-transplantation between the groups. 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
Fig 5: Forest plot comparing AST levels on the 3rd post operative day between the groups. 
 
 
 
 
Fig 6: Forest plot comparing length of ITU stay between the groups. 
 
 
 
 
Fig 7: Forest plot comparing length of hospital stay between the groups. 
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Fig 8: Forest plot comparing incidence of acute rejection episodes between the groups. 
 
 
 
 
 
